Adverse events43

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 43

Type	Event	Organ system	Group	Affected	At risk
serious	Neutropenia	Blood and lymphatic system disorders	Treatment (Glembatumumab Vedotin)	21	35
serious	Thrombocytopenia	Blood and lymphatic system disorders	Treatment (Glembatumumab Vedotin)	5	35
serious	Elevated ALT/AST	Gastrointestinal disorders	Treatment (Glembatumumab Vedotin)	22	35
serious	Nausea	Gastrointestinal disorders	Treatment (Glembatumumab Vedotin)	18	35
serious	Diarrhea	Gastrointestinal disorders	Treatment (Glembatumumab Vedotin)	11	35
serious	Constipation	Gastrointestinal disorders	Treatment (Glembatumumab Vedotin)	8	35
serious	Mucositis, oral	Blood and lymphatic system disorders	Treatment (Glembatumumab Vedotin)	6	35
serious	Vomiting	Gastrointestinal disorders	Treatment (Glembatumumab Vedotin)	5	35
serious	Alopecia	Skin and subcutaneous tissue disorders	Treatment (Glembatumumab Vedotin)	28	35
serious	Rash, maculopapular	Skin and subcutaneous tissue disorders	Treatment (Glembatumumab Vedotin)	19	35
serious	Pruritus	Skin and subcutaneous tissue disorders	Treatment (Glembatumumab Vedotin)	18	35
serious	Leukopenia	Blood and lymphatic system disorders	Treatment (Glembatumumab Vedotin)	24	35
serious	Anemia	Blood and lymphatic system disorders	Treatment (Glembatumumab Vedotin)	14	35
serious	Lymphopenia	Blood and lymphatic system disorders	Treatment (Glembatumumab Vedotin)	6	35
serious	Elevated ALP	Gastrointestinal disorders	Treatment (Glembatumumab Vedotin)	9	35
serious	Hyperbilirubinemia	Gastrointestinal disorders	Treatment (Glembatumumab Vedotin)	4	35
serious	Abdominal pain	Gastrointestinal disorders	Treatment (Glembatumumab Vedotin)	2	35
serious	Dry mouth	Gastrointestinal disorders	Treatment (Glembatumumab Vedotin)	2	35
serious	Oral pain	Gastrointestinal disorders	Treatment (Glembatumumab Vedotin)	2	35
serious	Fatigue	General disorders	Treatment (Glembatumumab Vedotin)	20	35

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02363283/events

API reference For AI assistants

Adverse events43

Sources 3

Read this list from software.